Biovica International – Positive Results With DiviTum® From New Pfizer Study Presented at the AACR Congress

April 17, 2018 | By forimmediaterele | Filed in: Press Releases.

Travel & Tourism Industry release:

UPPSALA, Sweden, April 17, 2018 /PRNewswire/ —

New results from a Pfizer study on Ibrance® (palbociclib, Pfizer) of women with metastatic breast cancer demonstrate that DiviTum can provide fast evaluation of biologic effect demonstrating CDK 4/6 inhibition.

Click here to read the full release with contact information on PR Newswire. Some releases are not in English.

To post and circulate your own press release on FIR and the eTN Network  please click here 

 


Comments are closed here.